
Sweden · Research startup
Strike Pharma AB is a Swedish biotech company founded in 2020 and based in Lund, with origins in Uppsala.
Funding reportedLast round: Undisclosed round
Strike Pharma AB is a Swedish biotech company founded in 2020 and based in Lund, with origins in Uppsala.
The company specializes in proprietary technology for targeted lipid nanoparticle (LNP) delivery, focusing on in vivo CAR-T therapies for autoimmune diseases and cancer. Its mission is to commercialize the Adaptable Drug Affinity Conjugate (ADACTM) technology platform, which supports precision medicine and individualized immunotherapeutic treatments tailored to the genetic profiles of patients' tumors. The core innovation of Strike Pharma is its ADACTM technology, which addresses critical challenges in drug manufacturing and delivery. This platform enables selective targeting of tumor cells and the delivery of RNA encapsulated in LNPs. Key developments include the STRIKE2001-KRAS clinical candidate for solid tumors and a bi-specific antibody for enhanced targeting. The company aims to provide personalized immunotherapies that increase therapeutic efficacy while minimizing side effects, positioning itself in a competitive landscape alongside major biotech firms.
Funding, as reported
From Strike Pharma AB's own website: 5 on the team.
What they build
Known for
lnp-ptag-bsab complexhealth caremodular peptide deliverybispecific antibodybiotechnology researchptag peptide tagrna payloadoff-the-shelf car-tautoimmune diseasepeptide conjugatesmedical researchnanoparticle therapycancer vaccine developmentautoimmune disease treatmentautoimmune disease therapyhospital & health care
Built with from their website
Google Tag ManagerWordPress.orgCloudFlareViewport MetaCloudFlare CDNMicrosoft ExchangeCloudflare InsightsMySQLUnpkgMicrosoft 365 Apps & Services
Mobile FriendlyOpen GraphjQueryRSSjQuery CDNCloudflare DNSGoogle AnalyticsHTTP/3
Add your raise, your deck and your story, and put Strike Pharma AB in front of investors. Or tell us what we have wrong.